Search tips
Search criteria 


Logo of ijpharsciHomeCurrent issueInstructionsArchives
Indian J Pharm Sci. 2010 May-Jun; 72(3): 371–375.
PMCID: PMC3003174

Evaluation of Antiseizure Activity of Essential Oil from Roots of Angelica archangelica Linn. in Mice


In the present study, the effect of essential oil of the root of Angelica archangelica Linn. was evaluated against electrically and chemically induced seizures. The seizures were induced in mice by maximal electroshock and pentylenetetrazol. The effect of essential oil of the root of Angelica archangelica on seizures was compared with standard anticonvulsant agents, phenytoin and diazepam. The essential oil of the root of Angelica archangelica suppressed duration of tonic convulsions and showed recovery in maximal electroshock induced seizures while it delayed time of onset of clonic convulsions and showed mortality protection in pentylenetetrazol induced seizures. The essential oil of the root of Angelica archangelica also produced motor impairment at the antiseizure doses. The study indicated that the essential oil exhibited antiseizure effect. The antiseizure effect may be attributed to the presence of terpenes in the essential oil.

Keywords: Angelica archangelica (Umbelliferae), convulsions, pentylenetetrazol, medicinal plants, maximal electroshock

Angelica archangelica Linn (Umbelliferae) is a perineal herbaceous plant[1] commonly known as Chorak. It is cultivated especially for the culinary uses and aromatherapy. It is reported to possess antimutagenic[2], antiulcerogenic[3], hepatoprotective[4], antiproliferative[5] antitumour[6], and cytotoxic[7] effects. Ayurvedic literature documents that A. archangelica exhibits significant influence on central nervous system. The essential oil of Angelica sinensis, another species of Angelica, showed the anxiolytic effect[8,9] in animal models.

In Indian system of medicine, A. archangelica and especially its roots are used in treatment of epilepsy[10]. Chemical studies have demonstrated that monoterpenes hydrocarbons are present in the essential oil of root of A. archangelica (AAO)[11]. Monoterpenes have shown protective effects against pentylenetetrazol-, picrotoxin- and N-methy-D-Aspartate-induced convulsions[12,13]. Further, chemical studies also demonstrated the presence of α-pinene, β-pinene, δ-3-carene, limonene, α-phellandrene, β-phellandrene, p-cymene[11,14] as the major components of the AAO. It is reported that some analogs of pinene prevent the audiogenic seizures in susceptible rats[15,16].

In view of these evidences, it is possible that AAO can exhibit seizure protective effect. The present study was, therefore, undertaken to evaluate the effect of AAO on experimentally induced seizures. Moreover, it was also assessed whether, at the anticonvulsant doses, AAO causes motor impairment.

The essential oil of root of A. archangelica (AAO) was obtained from Rakesh Industries, Kanpur, India. Phenytoin sodium was procured as gift sample from Anglo-French Drugs and Industries, Bengaluru while diazepam was procured from local pharmacy (Calmpose). Pentylenetetrazol was purchased from Sigma chemicals, USA. For administration purpose, AAO was diluted with arachis oil to obtain the desired doses. The other drugs were prepared freshly by dissolving in normal saline. All the drugs and AAO were injected intraperitoneally (i.p.).

Albino Swiss mice (20-30 g) of either sex (procured from Central Drug Research Institute, Lucknow, India) maintained in Central Animal Facility of the Institute were used throughout the study. The animals were maintained at constant room temperature (22±2°) and 12-h light/12-h dark cycle with food and water ad libitum. The experimental protocols were approved by the Institutional Animal Ethical Committee constituted for the control and supervision on experiments on animals.

The authenticity of the AAO was assessed by determining its physicochemical characteristics viz. refractive index, specific gravity, acid value and boiling point by standard conventional methods.

Acute toxicity study was performed in mice according to Staircase method. The dose was increased from 500 mg/kg to 2000 mg/kg through i.p. route (5 animals per dose). The mice were observed individually after dosing at least once during the first 30 min periodically during the first 24 h, with special attention given during the first 4h.

In Maximal electroshock (MES) induced seizures,[17] an electroconvulsive shock (50 mA for 0.2 sec) was delivered through corneal-electrode to induce hind limb tonic extensor phase (HLTE) in mice. Prior to delivery, the current output was checked by Multimeter. The current was delivered to 6 groups of mice (n=6) 30 min after i.p. administration of arachis oil (10 ml/kg) or AAO (50, 100, 200, 400 mg/kg) or phenytoin sodium (25 mg/kg). After the electric shock, the occurrence and duration of HLTE and incidence of mortality were noted. The animals that did not exhibit HLTE and death were considered protected.

In pentylenetetrazol (PTZ)-induced seizures[17], PTZ (80 mg/kg, CD99 dose) was injected i.p. to induce general clonic convulsions in mice. After PTZ injection, the mice were observed for onset and duration of general clonus and mortality. PTZ was administered to 7 groups of mice (n = 6) 30 min after i.p. administration of arachis oil (10 ml/kg) or AAO (50, 100, 200, 400, 500 mg/kg) or diazepam (4 mg/kg). If no general clonus occurred, the animal were considered protected.

The rota-rod test[18] was used to determine the effect of AAO on motor incordination. Mice were placed on horizontal metal-coated rod (2.5 cm diameter) rotating at speed of 22 rpm. The time, each mouse was able to maintain its balance walking on top of the rod, was measured and cut off time was kept 300 sec. Before the beginning of all experiments, the riding ability of the animals on rota-rod was checked. Thus, the mice were initially put on a rotating rod, and mice that immediately dropped off (within 60 sec.) were excluded from the experiment. The test was conducted on 7 groups (n = 6) of previously screened mice, 30 min after the injection of arachis oil (10 ml/kg) or AAO (50, 100, 200, 400, 500 mg/kg) or diazepam (4 mg/kg).

The traction test[19] was also used to determine the effect of AAO on motor incordination. Forepaws of a mouse were placed on a 15 cm long twisted wire rigidly supported and 20 cm above the table top. Normal mice grasped the wire with forepaws and when allowed to hang free, placed at least one hind foot on the wire within 5 sec. Inability to put up at lest one hind foot was considered failure to the traction. The test was conducted on 7 groups (n = 6) previously screened mice, 30 min after the injection of arachis oil (10 ml/kg) or AAO (50, 100, 200, 400, 500 mg/kg) or diazepam (4 mg/kg).

The data from MES and PTZ test were analyzed by Chi Square test for the assessment of protection of convulsion. The ED50 and TD50 values were calculated by Litchfield and Wilcoxan method. The data from traction test were analyzed by Chi Square test while the data from rota rod test were analyzed by one way ANOVA followed by Dunnett multiple comparisons test. A difference of p<0.05 was considered significant in all cases.

The assessment of physicochemical parameters showed that AAO exhibited light greenish yellow colour, strong aromatic odour, refractive index (1.46900-1.47800), specific gravity (0.85000-0.88000), boiling point (82±2°), and acid value (4.0-4.2). These values were similar to those reported earlier[1] indicating the authenticity of the AAO.

The toxicity studies revealed that maximum tolerable dose for AAO was more than 2000 mg/kg. No signs of toxicity or moribund state were found at all the dose of AAO tested. Therefore, the approximate LD50 is more than 2000 mg/kg.

The Chi-square analysis indicated that AAO treatment exhibited significant antiseizure activity [(df= 24.79, 5), p<0.05] (Table 1) against MES-induced seizure with an ED50 of 373.53 mg/kg. The AAO also prevented clonic seizures induced by PTZ (p<0.05, df= 29.36, 6, Table 2) with an ED50 value 214.62 mg/kg for the AAO. Phenytoin and diazepam (positive controls) produced 100% protection against seizures induced by MES and PTZ.


In traction test, the Chi-square analysis indicated that, the AAO exhibited significant (p<0.05, df= 25.33, 6) sedation and motor impairment. AAO demonstrated dose related decrease in the time of holding compared to vehicle. AAO 100, 200 and 400 mg/kg showed 20, 20 and 80% failure respectively and AAO 500 mg/kg indicated 100% failure to put at least one hind limb on wire Thus, the TD50 of AAO in traction test was found to be 277.27 mg/kg. In rota- rod test, one-way ANOVA showed that AAO has significant influence on the motor function (p<0.05). Dunnett’s multiple comparisons indicated AAO showed a significant decline (p<0.05) in the motor function maximum at the doses which produced antiseizure effect (fig. 1).

Fig. 1
Effect of AAO on rota rod test Separate groups of mice were injected with vehicle (10 ml/kg, i.p.) or diazepam (4 mg/kg, i.p.) or increasing doses of AAO (50-500 mg/kg, i.p.), and 30 min thereafter motor incordination was tested on rota rod. Each bar ...

The MES test is used primarily as an indication for compounds which are effective in grand mal epilepsy while the PTZ test represents a valid model for human generalized myoclonic and also absence seizures[20]. The present study revealed that the essential oil of the root of Angelica archangelica attenuated both MES-induced tonic and PTZ-induced clonic seizures indicating that AAO possesses antiseizure activity. These findings corroborate well with a recent study that demonstrated the anticonvulsant effect of imperatorin (a furanocoumarin isolated from fruits of Angelica archangelica) in the mouse maximal electroshock seizure threshold model[21] and support the antiseizure activity Angelica archangelica. However, it is not clear that how does AAO exhibit antiseizure activity.

As mentioned earlier, AAO contains more than 60% monoterpenes[11] and monoterpenes have been found to show protective effects against PTZ, picrotoxin-and NMDA-induced convulsions[12,13]. Modulations of glutamatergic and GABAergic transmission are mechanisms indicated for anticonvulsant action of the monoterpenes[13,22,23]. Therefore, it is possible that the antiseizure effect of AAO can be due to the presence of monoterpenes present in AAO and subsequent modulation of glutamatergic and GABAergic transmission.

α-pinene is one of the major constituent of AAO[11]. It is reported that some analogs of pinene prevent the audiogenic seizures in susceptible rats[15] which further strengthens the anti-seizure potential of AAO and it may be related to terpenoids present in the oil. The investigations further revealed that AAO produced motor impairment at antiseizure doses. Some terpenes such as eugenol and anethol have anesthetic, sedative and muscle relaxant effects[24,25]. The terpenes present in the essential oil may be responsible for the observed motor impairment subsequent to CNS depression. Thus, the present investigations conclude that AAO exhibits significant antiseizure activity against chemically and electrically induced seizures in mice and the same can be attributed to terpenes especially monoterpenes present in the Angelica essential oil.


Pathak, et al.: Antiseizure Activity of Angelica archangelica


1. The Wealth of India, A dictionary of Indian raw materials and industrial products raw materials. A revised ed. Vol 1. New Delhi: Council of Scientifi c and Industrial Research; 2003. pp. 275–6.
2. Salikhova RA, Poroshenko GG. Antimutagenic properties of Angelica archangelica L. Vestn Ross Akad Med Nauk. 1995;1:58–61. [PubMed]
3. Khayyal MT, el-Ghazaly MA, Kenawy SA, Seif-el-Nasr M, Mahran LG, Kafafi YA, et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittelforschung. 2001;51:545–53. [PubMed]
4. Yeh ML, Liu CF, Huang CL, Huang TC. Hepatoprotective effect of Angelica archangelica in chronically ethanol-treated mice. Pharmacology. 2003;68:70–3. [PubMed]
5. Sigurdsson S, Ogmundsdottir HM, Gudbjarnason S. Antiproliferative effect of Angelica archangelica fruits. Z Naturforsch [C] 2004;59:523–7. [PubMed]
6. Sigurdsson S, Ogmundsdottir HM, Hallgrimsson J, Gudbjarnason S. Antitumour activity of Angelica archangelica leaf extract. In Vivo. 2005;19:191–4. [PubMed]
7. Sigurdsson S, Ogmundsdottir HM, Gudhjarnason S. The cytotoxic effect of two chemotypes of essential oils from the fruits of Angelica archangelica L. Anticancer Res. 2005;25B:1877–80. [PubMed]
8. Chen SW, Min L, Li WJ, Kong WX, Li JF, Zhang YJ. The effects of angelica essential oil in three murine tests of anxiety. Pharmacol Biochem Behav. 2004;79:377–82. [PubMed]
9. Min L, Chen SW, Li WJ, Wang R, Li YL, Wang WJ, et al. The effects of angelica essential oil in social interaction and hole-board tests. Pharmacol Biochem Behav. 2005;81:838–42. [PubMed]
10. Sharma PV. Medhyadi Varg. In: Sharma PV, editor. Dravya Gun-Vijnana, Vegetable drugs. Vol 2. Varanasi: Chaukhambha Bharti Academy; 2005. pp. 34–5.
11. Nivinskiene O, Butkiene R, Mockute D. Changes in the chemical composition of essential oil of Angelica archangelica L. roots during storage. Chemija (Vilnius) 2003;14:52–6.
12. Librowski T, Czarnecki R, Mendyk A, Jastrzebska M. Influence of new monoterpene homologues of GABA on the central nervous system activity in mice. Pol J Pharmacol. 2000;52:317–21. [PubMed]
13. Brum LF, Elisabetsky E, Souza D. Effects of linalool on [(3) H] MK801 and [(3) H] muscimol binding in mouse cortical membranes. Phytother Res. 2001;15:422–5. [PubMed]
14. Chalchat JC, Garry RP. Essential oil of Angelica roots (Angelica archangelica L.): optimization of distillation, location in plant and chemical composition. J Essen Oil Res. 1997;9:311–9.
15. Consroe P, Martin A, Singh V. Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol. 1981;21:428S–36S. [PubMed]
16. Sayyah M, Nadjafnia L, Kamalinejad M. Anticonvulsant activity and chemical composition of Artemisia dracunculus L. essential oil. J Ethnopharmacol. 2004;94:283–7. [PubMed]
17. Kulkarni SK. Handbook of experimental pharmacology. 3rd ed. New Delhi: Vallabh Prakashan; 1999. pp. 131–4.
18. Cartmell SM, Gelgor L, Mitchell D. A revised- rota rod procedure for measuring the effect of antinociceptive drugs on motor function in the rat. J Pharmacol Methods. 1991;26:149–59. [PubMed]
19. Hosseinzadeh H, Nassiri Asl M. Anticonvulsant, sedative and muscle relaxant effects of carbenoxolone in mice. BMC Pharmacol. 2003;3:3. [PMC free article] [PubMed]
20. Loscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs. A proposal based on experimental and clinical considerations? Epilepsy Res. 1988;3:145–81. [PubMed]
21. Luszczki JJ, Glowniak K, Czuczwar SJ. Time-course and dose-response relationships of imperatorin in the mouse maximal electroshock seizure threshold model. Neurosci Res. 2007;59:18–22. [PubMed]
22. Wie MB, Won MH, Lee KH, Shin JH, Lee JC, Suh HW, et al. Eugenol protects neuronal cells from excitotoxic and oxidative injury in primary cortical cultures. Neurosci Lett. 1997;225:93–6. [PubMed]
23. Szabadics J, Erdelyi L. Pre- and postsynaptic effects of eugenol and related compounds on Helix pomatia L. neurons. Acta Biol Hung. 2000;51:265–73. [PubMed]
24. Boissier JR, Simon P, Le Bourhis B. Experimental psychotropic action of cis- and trans-isomers of anethole. Therapie. 1967;22:309–23. [PubMed]
25. Dallmeier K, Carlini EA. Anesthetic, hypothermic, myorelaxant and anticonvulsant effects of synthetic eugenol derivatives and natural analogues. Pharmacology. 1981;22:113–27. [PubMed]

Articles from Indian Journal of Pharmaceutical Sciences are provided here courtesy of Medknow Publications